Extended Anticoagulation for Recurrent Deep Vein Thrombosis

Introduction to Extended Anticoagulation

The American College of Chest Physicians recommends indefinite anticoagulation for patients with recurrent unprovoked deep vein thrombosis (DVT), given the high risk of recurrence and the benefits of extended anticoagulation, with a Grade 1B recommendation for low bleeding risk and Grade 2B for moderate bleeding risk 1, 2
Minor transient risk factors, such as a six-hour flight, do not substantially reduce recurrence risk compared to truly unprovoked events, and guidelines suggest against stopping anticoagulation at 3 months for VTE provoked by minor transient factors 1, 3

Having a second unprovoked DVT is the strongest indication for indefinite anticoagulation, with the CHEST guidelines providing a Grade 1B recommendation for extended anticoagulation in patients with a second unprovoked VTE and low bleeding risk 2
The annual recurrence risk if anticoagulation is stopped exceeds 10-15%, far outweighing typical bleeding risks, with a strong recommendation for extended anticoagulation in patients with recurrent unprovoked VTE 4, 3

The American College of Chest Physicians suggests reduced-dose apixaban (2.5 mg twice daily) over full-dose for extended-phase anticoagulation, with a weak recommendation and very low-certainty evidence 1

The American College of Chest Physicians recommends annual reassessment of bleeding risk factors, including age, previous major bleeding episodes, concomitant antiplatelet therapy, and renal or hepatic impairment, to determine the need for extended anticoagulation 1, 3
Low bleeding risk factors, such as age <70 years, no previous major bleeding episodes, and good medication adherence, favor indefinite therapy, while high bleeding risk factors, such as age ≥80 years, previous major bleeding, and severe renal or hepatic impairment, may favor stopping at 3 months 3

Indefinite anticoagulation means no scheduled stop date, potentially lifelong or until bleeding risk becomes prohibitive, with mandatory annual reassessment of bleeding risk, medication adherence, renal function, and any new medical conditions 4, 3, 1, 5
The benefit of anticoagulation persists only while anticoagulation is continued, and stopping restarts the high recurrence risk immediately, with a strong recommendation for indefinite anticoagulation in patients with recurrent unprovoked VTE 4, 3